On June 18, 2026, the Federal Trade Commission (FTC) announced that it would allow Aurobindo Pharma Limited’s approximately $250 million acquisition of Lannett Company, Inc. to proceed, subject to a proposed consent order requiring Aurobindo to divest four overlapping generic pharmaceutical products to Quagen Pharmaceuticals, LLC. The Commission voted 2-0 to issue an administrative complaint and accept the consent agreement for a 30-day public comment period.
The settlement represents the pro-remedy approach the current FTC has signaled it prefers in merger review: a structural divestiture of the entire competitive overlap to a vetted, experienced upfront buyer, negotiated during the investigation and in place before any complaint was issued. For dealmakers, particularly in generic pharmaceuticals and other industries where overlaps are discrete and identifiable, the outcome is a reminder that a full divestiture to a credible buyer, raised early, remains the most reliable path to clearance without litigation.
Background
Aurobindo and Lannett are both generic-drug manufacturers that develop, make, and sell pharmaceutical products in the U.S. By prescriptions dispensed, Aurobindo is the largest supplier of generic drugs in the country, while Lannett is a long-established U.S. generics company. The two directly compete as suppliers of many overlapping products, prompting the FTC’s review of Aurobindo’s $250 million buy of Lannett. The agency’s investigation focused on four generic products for which Aurobindo and Lannett are among only a small number of suppliers.
The complaint advanced a conventional horizontal theory of harm: in each of the product markets, Aurobindo and Lannett are among a limited set of significant suppliers, and combining them would eliminate direct competition, reduce the number of independent competitors, and increase the likelihood of both unilateral price increases and coordinated conduct, potentially resulting in higher prices to consumers. Notably, some of the generic products at issue had as many as six suppliers. However, a combination would have given the parties a significant combined share in those markets, reinforcing the case for relief and reflecting the FTC’s focus on market realities over competitor count alone.
The Fix
To resolve these concerns, the proposed remedy requires Aurobindo to divest the four products—together with the associated U.S. Food and Drug Administration (FDA) approvals, IP, manufacturing know-how, and related assets—to Quagen Pharmaceuticals, LLC, an established generic-drug company with its own FDA-approved manufacturing facilities. The 10-year order is backed by a package of provisions common in FTC pharmaceutical divestitures: transition services and supply at cost to keep the divested products on the market during the handoff, a technology-transfer obligation to enable continued, independent manufacturing, a 10-year bar on reacquiring the divested products, and an FTC-appointed monitor to oversee compliance.
Notably, the remedy here did not materialize “on the courthouse steps,” the kind of late-stage proposal the FTC has resisted, as in GTCR/Surmodics. Instead, the timing of the divestiture agreement, executed roughly six weeks before the Commission’s complaint and order, indicates the parties engaged early to negotiate the products for divestiture and to identify Quagen as an appropriate buyer. In other words, the generics manufacturers allowed the FTC to vet both the structural fix and the purchaser during its investigation, clearing the way to settlement.
The Commission’s 2-0 vote and the accompanying statement from Bureau of Competition Director Daniel Guarnera—emphasizing the agency’s focus on protecting patients from higher generic-drug prices—reflect how the agency views a remedy of this kind: not as a grudging concession that lets a problematic deal slip through, but rather as an enforcement win that preserves competition across four product markets while clearing the way for a lawful transaction to close.
Settlement Signals
The order fits squarely with the key themes of the FTC’s May 2026 workshop on last-minute antitrust remedy proposals, where the Commission said it would engage constructively on remedies that are structural, vetted, and raised early. The order also signals the agency’s priorities; Director Guarnera’s emphasis on drug costs is a reminder that healthcare remains an area of enforcement scrutiny. The encouraging lesson for merging parties is that those who work with the agency to develop a complete fix and identify a ready, capable buyer can timely close a deal.
The contrast with GTCR/Surmodics is instructive. There, the parties proposed only a partial divestiture after the FTC sued, “litigating the fix,” and ultimately prevailed when the court accepted their remedy over the agency’s objection. Aurobindo and Lannett took the opposite (and, from the agency’s perspective, preferred) path, offering a complete structural divestiture and identifying a buyer for the assets during the FTC’s investigation. Both routes can get a deal across the finish line, but the Aurobindo/Lannett model avoids the cost, delay, and uncertainty of litigation.
Takeaways
Two practical points emerge. First, generic pharmaceutical overlaps continue to draw scrutiny, and the FTC will look hard at markets that are already concentrated or indicate potential market power. Second, the credibility and capability of the divestiture buyer are central: selecting an experienced acquirer such as Quagen and working cooperatively with the FTC on a divestiture agreement during the investigation can materially smooth the path to clearance.
Parties contemplating transactions that present horizontal overlaps, especially in generic pharmaceuticals, medical devices, and other life sciences markets where the FTC has remained especially active, should engage antitrust counsel early to assess risk and the potential for divestiture, and develop a remedy strategy before, rather than after, the agency’s concerns crystallize.
For more information, please contact any member of the firm’s Antitrust and Competition practice.
